ADMA Biologics Company Profile (NASDAQ:ADMA)

About ADMA Biologics

ADMA Biologics logoADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADMA
  • CUSIP:
Key Metrics:
  • Previous Close: $4.78
  • 50 Day Moving Average: $5.08
  • 200 Day Moving Average: $5.67
  • 52-Week Range: $4.15 - $8.85
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.92
  • P/E Growth: 0.00
  • Market Cap: $61.60M
  • Outstanding Shares: 12,886,000
  • Beta: 2.79
Profitability:
  • Net Margins: -198.45%
  • Return on Equity: -6,405.90%
  • Return on Assets: -76.16%
Debt:
  • Debt-to-Equity Ratio: -92.07%
  • Current Ratio: 2.76%
  • Quick Ratio: 2.25%
Additional Links:
Companies Related to ADMA Biologics:

Analyst Ratings

Consensus Ratings for ADMA Biologics (NASDAQ:ADMA) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $13.00 (171.97% upside)

Analysts' Ratings History for ADMA Biologics (NASDAQ:ADMA)
Show:
DateFirmActionRatingPrice TargetDetails
1/23/2017Maxim GroupUpgradeHold -> Buy$13.00View Rating Details
8/1/2016Raymond James Financial, Inc.DowngradeStrong-Buy -> Market PerformView Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for ADMA Biologics (NASDAQ:ADMA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2017        
8/12/2016Q2($0.39)($0.50)ViewN/AView Earnings Details
5/13/2016Q1($0.37)($0.43)ViewN/AView Earnings Details
3/23/2016Q415($0.47)($0.58)$30.00 millionViewN/AView Earnings Details
11/10/2015Q315($0.39)($0.48)$1.50 million$1.85 millionViewN/AView Earnings Details
8/11/2015Q215($0.36)($0.44)$1.50 million$1.30 millionViewN/AView Earnings Details
5/12/2015Q115($0.38)($0.37)$1.50 million$1.50 millionViewN/AView Earnings Details
3/9/2015($0.38)($0.38)ViewN/AView Earnings Details
11/10/2014($0.37)($0.36)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ADMA Biologics (NASDAQ:ADMA)
Current Year EPS Consensus Estimate: $-1.57 EPS
Next Year EPS Consensus Estimate: $-1.22 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.37)($0.37)($0.37)
Q3 20161($0.38)($0.38)($0.38)
Q4 20161($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ADMA Biologics (NASDAQ:ADMA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ADMA Biologics (NASDAQ:ADMA)
Insider Ownership Percentage: 60.44%
Institutional Ownership Percentage: 73.57%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/3/2016Adam S GrossmanCEOBuy200,000$6.50$1,300,000.00View SEC Filing  
5/3/2016Brian LenzCFOBuy2,500$6.50$16,250.00View SEC Filing  
5/3/2016James MondCMOBuy770$6.50$5,005.00View SEC Filing  
5/3/2016Jerrold B GrossmanDirectorBuy45,769$6.50$297,498.50View SEC Filing  
12/8/2015Adam S. GrossmanCEOBuy500$9.00$4,500.00View SEC Filing  
12/7/2015Jerrold B GrossmanDirectorBuy500$9.01$4,505.00View SEC Filing  
12/2/2015Adam S GrossmanCEOBuy2,250$9.15$20,587.50View SEC Filing  
12/2/2015Brian LenzCFOBuy1,000$9.15$9,150.00View SEC Filing  
12/2/2015Jerrold B GrossmanDirectorBuy6,000$9.16$54,960.00View SEC Filing  
12/1/2015Adam S GrossmanCEOBuy1,800$9.17$16,506.00View SEC Filing  
11/25/2015Adam S GrossmanCEOBuy1,800$9.18$16,524.00View SEC Filing  
11/20/2015Adam S GrossmanCEOBuy3,861$9.21$35,559.81View SEC Filing  
3/19/2015Adam S GrossmanCEOBuy2,000$8.50$17,000.00View SEC Filing  
3/17/2015Adam S GrossmanCEOBuy5,500$7.98$43,890.00View SEC Filing  
3/17/2015Jerrold B GrossmanDirectorBuy500$8.01$4,005.00View SEC Filing  
3/16/2015Adam S GrossmanCEOBuy8,800$8.03$70,664.00View SEC Filing  
3/16/2015James MondCMOBuy1,250$8.02$10,025.00View SEC Filing  
3/16/2015Lawrence P GuiheenDirectorBuy1,000$7.96$7,960.00View SEC Filing  
3/13/2015Eric I RichmanDirectorBuy3,500$7.88$27,580.00View SEC Filing  
9/12/2014Adam S GrossmanCEOBuy4,300$9.57$41,151.00View SEC Filing  
8/22/2014Adam S GrossmanCEOBuy1,000$9.50$9,500.00View SEC Filing  
8/14/2014Adam S GrossmanCEOBuy2,100$9.77$20,517.00View SEC Filing  
6/18/2014Adam S GrossmanCEOBuy1,875$9.59$17,981.25View SEC Filing  
5/22/2014Adam S GrossmanCEOBuy4,226$8.15$34,441.90View SEC Filing  
5/15/2014Adam S GrossmanCEOBuy13,400$7.50$100,500.00View SEC Filing  
5/14/2014Brian LenzCFOBuy1,000$7.50$7,500.00View SEC Filing  
5/14/2014James MondCMOBuy1,315$7.60$9,994.00View SEC Filing  
12/10/2013Jerrold B GrossmanDirectorBuy3,650$7.30$26,645.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ADMA Biologics (NASDAQ:ADMA)
DateHeadline
News IconAnalysts Peer Into Their Crystal Balls For ADMA Biologics Inc (NASDAQ:ADMA): Where Is It headed? - Winfield Review (NASDAQ:ADMA)
winfieldreview.com - February 23 at 3:21 PM
News IconADMA Biologics Inc ADMA Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:ADMA)
www.bioportfolio.com - February 22 at 11:43 AM
News IconShould You Sell ADMA Biologics Inc Based On Current Broker Views? - NewsDen (NASDAQ:ADMA)
newsden.net - February 21 at 3:37 PM
marketexclusive.com logoADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors ... - Market Exclusive (NASDAQ:ADMA)
marketexclusive.com - February 20 at 5:51 AM
biz.yahoo.com logoADMA BIOLOGICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:ADMA)
biz.yahoo.com - February 18 at 7:49 AM
News IconStock Focus: Watching the Levels for ADMA Biologics, Inc. (NASDAQ:ADMA) - Piedmont Register (NASDAQ:ADMA)
piedmontregister.com - February 17 at 9:41 AM
streetinsider.com logoForm 4 ADMA BIOLOGICS, INC. For: Feb 14 Filed by: LENZ BRIAN - StreetInsider.com (NASDAQ:ADMA)
www.streetinsider.com - February 17 at 9:41 AM
streetinsider.com logoForm 4 ADMA BIOLOGICS, INC. For: Feb 14 Filed by: Guiheen Lawrence P. - StreetInsider.com (NASDAQ:ADMA)
www.streetinsider.com - February 17 at 9:41 AM
News IconIs The Sell-Side Predicting That ADMA Biologics Inc (NASDAQ:ADMA) Will Move Higher? - Winfield Review (NASDAQ:ADMA)
winfieldreview.com - February 16 at 3:23 PM
News IconAre Analysts Optimistic About Where ADMA Biologics Inc (NASDAQ:ADMA) is Heading? - Winfield Review (NASDAQ:ADMA)
winfieldreview.com - February 15 at 1:38 AM
News IconBlood Plasma Industry Sales, Supply and Consumption 2017 Analysis and Forecasts to 2022 (NASDAQ:ADMA)
empowerednews.net - February 8 at 8:27 PM
News IconCould ADMA Biologics Inc (ADMA) Change Direction After This Wedge Down Pattern - The Randolph Guide (NASDAQ:ADMA)
randolphguide.com - January 31 at 3:24 PM
News IconStock Update: Estimates & Target in Focus for ADMA Biologics Inc (NASDAQ:ADMA) - Aiken Advocate (NASDAQ:ADMA)
aikenadvocate.com - January 30 at 3:31 PM
News IconStock Update: Estimates & Target in Focus for ADMA Biologics Inc ... - Aiken Advocate (NASDAQ:ADMA)
aikenadvocate.com - January 30 at 3:31 PM
prnewswire.com logoBlood Plasma Market 2017-2021 Key Regions Competitive Analysis (NASDAQ:ADMA)
www.prnewswire.com - January 27 at 9:45 PM
News IconStock Watch for ADMA Biologics, Inc. (NASDAQ:ADMA) - The Tribune (NASDAQ:ADMA)
lakecitytribune.com - January 27 at 3:43 PM
kcregister.com logoTop Wall Street Stories: ADMA Biologics, Inc. (NASDAQ:ADMA), Chesapeake Granite Wash Trust (NYSE:CHKR ... - KC Register (NASDAQ:ADMA)
www.kcregister.com - January 25 at 3:24 PM
streetinsider.com logoADMA Biologics (ADMA) to Acquire Assets from Biotest Pharmaceuticals (NASDAQ:ADMA)
www.streetinsider.com - January 25 at 1:43 AM
kcregister.com logoStocks Under Wall Street's Radar: ADMA Biologics, Inc. (NASDAQ:ADMA), Ophthotech Corporation (NASDAQ:OPHT ... - KC Register (NASDAQ:ADMA)
www.kcregister.com - January 24 at 8:40 PM
News IconEarnings in Full Force, Analysts Take Aim at ADMA Biologics Inc (NASDAQ:ADMA) - Wall Street Beacon (NASDAQ:ADMA)
wsbeacon.com - January 24 at 3:39 PM
directorstalkinterviews.com logoADMA Biologics Inc 151% Potential Upside Now Implied by Maxim Group - DirectorsTalk Interviews (NASDAQ:ADMA)
www.directorstalkinterviews.com - January 24 at 3:39 PM
finanznachrichten.de logoDGAP-Adhoc: Biotest AG: Biotest verkauft US-Therapiegeschäft an ... - FinanzNachrichten.de (NASDAQ:ADMA)
www.finanznachrichten.de - January 24 at 1:25 AM
investornewswire.com logoADMA Biologics Inc (NASDAQ:ADMA) EPS Target Set At $-0.26 - Investor Newswire (NASDAQ:ADMA)
www.investornewswire.com - January 23 at 8:24 PM
finance.yahoo.com logoADMA Biologics upgraded by Maxim Group (NASDAQ:ADMA)
finance.yahoo.com - January 23 at 8:24 PM
biz.yahoo.com logoADMA BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secu (NASDAQ:ADMA)
biz.yahoo.com - January 23 at 8:24 PM
News IconLooking Ahead for ADMA Biologics Inc (NASDAQ:ADMA); Are These Shares Ready to Go Higher? - Aiken Advocate (NASDAQ:ADMA)
aikenadvocate.com - January 23 at 3:21 PM
uk.finance.yahoo.com logoDGAP-News: Biotest AG / Key word(s): Disposal - Yahoo Finance UK (NASDAQ:ADMA)
uk.finance.yahoo.com - January 23 at 3:21 PM
reuters.com logoBRIEF-Biotest to sell US therapy business to ADMA Biologics Inc. - Reuters (NASDAQ:ADMA)
www.reuters.com - January 23 at 3:21 PM
finance.yahoo.com logoADMA Biologics to Acquire Certain Assets from Biotest Pharmaceuticals Corporation and Become a Vertically Integrated Commercial Plasma Products Company (NASDAQ:ADMA)
finance.yahoo.com - January 23 at 3:21 PM
finance.yahoo.com logo7:01 am ADMA Biologics announces transaction w/ Biotest Pharmaceuticals Corporation; co will acquire certain Biotest assets in exchange for shares of its common stock (NASDAQ:ADMA)
finance.yahoo.com - January 23 at 3:21 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on ADMA Biologics Inc (NASDAQ:ADMA) - Wall Street Beacon (NASDAQ:ADMA)
wsbeacon.com - January 20 at 3:23 PM
News IconAnalysts Watch ADMA Biologics Inc (ADMA) And Issue New Targets ... - NewsDen (NASDAQ:ADMA)
newsden.net - January 18 at 3:49 PM
News IconWill This Stock Move with Earnings? The Sell-side chimes in on ADMA Biologics Inc (NASDAQ:ADMA) Shares - Aiken Advocate (NASDAQ:ADMA)
aikenadvocate.com - January 17 at 10:15 AM
News IconUpside Alert: Delving into Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - Prospect Journal (NASDAQ:ADMA)
prospectjournal.com - January 17 at 10:15 AM
News IconWill The Needle Move For ADMA Biologics Inc (NASDAQ:ADMA) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:ADMA)
wsbeacon.com - January 17 at 10:15 AM
News IconShort Interest Watching: Adma Biologics Incorporated (NASDAQ:ADMA) Shorts Decreased by 4.61% After Short Covering - Baxley Report (NASDAQ:ADMA)
baxleyreport.com - January 12 at 3:21 PM
News IconStock Edging Lower Out Of The Gate: ADMA Biologics, Inc. (NASDAQ:ADMA) - Wall Street Beacon (NASDAQ:ADMA)
wsbeacon.com - January 12 at 3:21 PM
investornewswire.com logoADMA Biologics Inc (NASDAQ:ADMA) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:ADMA)
www.investornewswire.com - January 4 at 8:27 PM
News IconVC Score in Review for ADMA Biologics, Inc. (NASDAQ:ADMA) - Wall Street Beacon (NASDAQ:ADMA)
wsbeacon.com - January 3 at 8:41 PM
News IconEquity Review: Looking Closer at Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - Liberty News (NASDAQ:ADMA)
libertynewsrecord.com - December 21 at 3:40 PM
investornewswire.com logoSentiments And Ratings Alert: ADMA Biologics Inc (NASDAQ:ADMA) - Investor Newswire (NASDAQ:ADMA)
www.investornewswire.com - December 21 at 10:54 AM
News IconStock Levels in View for ADMA Biologics, Inc. (NASDAQ:ADMA) - OIB News (NASDAQ:ADMA)
oibnews.com - December 20 at 8:15 PM
News IconGrowth Story Unfolding for ADMA Biologics, Inc. (NASDAQ:ADMA) - Prospect Journal (NASDAQ:ADMA)
prospectjournal.com - December 20 at 3:15 PM
News IconMarket Focus: Watching Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - Liberty News (NASDAQ:ADMA)
libertynewsrecord.com - December 20 at 3:15 PM
News IconLevels in View for ADMA Biologics, Inc. (NASDAQ:ADMA) - Business Daily Leader (NASDAQ:ADMA)
businessdailyleader.com - December 18 at 8:18 PM
stocksdaily.net logoCan ADMA Biologics Inc (NASDAQ:ADMA) Post EPS Of $-0.33? - Stocks Daily (NASDAQ:ADMA)
www.stocksdaily.net - December 18 at 8:18 PM
News IconValue Score Review for ADMA Biologics, Inc. (NASDAQ:ADMA) - Highland Digest (NASDAQ:ADMA)
highlanddigest.com - December 18 at 3:18 PM
News IconEquity Check-in on Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) - OIB News (NASDAQ:ADMA)
oibnews.com - December 16 at 8:29 PM
News IconChecking on Levels for ADMA Biologics, Inc. (NASDAQ:ADMA) - Business Daily Leader (NASDAQ:ADMA)
businessdailyleader.com - December 15 at 3:25 PM
insidermonkey.com logoADMA Biologics Inc (ADMA): Does It Stack Up To Its Peers? (NASDAQ:ADMA)
www.insidermonkey.com - December 15 at 3:25 PM

Social

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

Where is ADMA Biologics' stock going? Where will ADMA Biologics' stock price be in 2017?

2 analysts have issued 12-month target prices for ADMA Biologics' shares. Their predictions range from $13.00 to $13.00. On average, they expect ADMA Biologics' share price to reach $13.00 in the next year.

When will ADMA Biologics announce their earnings?

ADMA Biologics is scheduled to release their next quarterly earnings announcement on Tuesday, March, 21st 2017.

Who owns ADMA Biologics stock?

ADMA Biologics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Broadfin Capital LLC (8.64%), Perceptive Advisors LLC (5.60%), FMR LLC (3.28%) and Franklin Resources Inc. (2.79%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond, Jerrold B Grossman and Lawrence P Guiheen.

Who bought ADMA Biologics stock? Who is buying ADMA Biologics stock?

ADMA Biologics' stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond, Jerrold B Grossman and Lawrence P Guiheen.

How do I buy ADMA Biologics stock?

Shares of ADMA Biologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ADMA Biologics stock cost?

One share of ADMA Biologics stock can currently be purchased for approximately $4.78.

ADMA Biologics (NASDAQ:ADMA) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Earnings History Chart

Earnings by Quarter for ADMA Biologics (NASDAQ:ADMA)

Dividend History Chart

Dividend Payments by Quarter for ADMA Biologics (NASDAQ:ADMA)

Last Updated on 2/24/2017 by MarketBeat.com Staff